Stock NGEN NERVGEN PHARMA CORP.
Add to a list
To use this feature you must be a member
Log inSign up

Financials NervGen Pharma Corp.

Equities

NGEN

CA64082X2032

Biotechnology & Medical Research

Market Closed - Toronto S.E.
Other stock markets
 03:57:02 2024-04-26 pm EDT 		5-day change 1st Jan Change
2.11 CAD +4.46% Intraday chart for NervGen Pharma Corp. -5.38% -21.85%
Apr. 17 NervGen Reports FY 2023 Net Loss of $0.38 Per Share, Provides Operations Update MT
Apr. 17 NervGen Pharma Corp. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Valuation

Fiscal Period: December 2020 2021 2022 2023 2024
Capitalization 1 78.31 123.8 93.89 160.9 147.5
Enterprise Value (EV) 1 78.31 123.8 93.89 160.9 147.5
P/E ratio -6.37 x - - - -
Yield - - - - -
Capitalization / Revenue - - - - -
EV / Revenue - - - - -
EV / EBITDA - -14.1 x -4.66 x -13.9 x -9.34 x
EV / FCF - -14,971,057 x -5,272,962 x - -
FCF Yield - -0% -0% - -
Price to Book - - - - -
Nbr of stocks (in thousands) 35,117 45,362 58,679 59,606 69,928
Reference price 2 2.230 2.730 1.600 2.700 2.110
Announcement Date 4/8/21 2/28/22 3/30/23 4/17/24 -
1CAD in Million2CAD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2020 2021 2022 2023 2024
Net sales 1 - - - - -
EBITDA 1 - -8.753 -20.13 -11.59 -15.8
EBIT - -12.81 -23.03 - -
Operating Margin - - - - -
Earnings before Tax (EBT) - - - - -
Net income -11.19 - - - -
Net margin - - - - -
EPS -0.3500 - - - -
Free Cash Flow - -8.272 -17.81 - -
FCF margin - - - - -
FCF Conversion (EBITDA) - - - - -
FCF Conversion (Net income) - - - - -
Dividend per Share - - - - -
Announcement Date 4/8/21 2/28/22 3/30/23 4/17/24 -
1CAD in Million
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4
Net sales 1 - - - - - -
EBITDA 1 -3.656 -3.059 -4.196 -5.448 -4.279 -6.212
EBIT 1 -3.667 -4.147 -5.004 -6.313 -4.924 -6.784
Operating Margin - - - - - -
Earnings before Tax (EBT) -3.599 - - - - -
Net income -3.599 - - - - -
Net margin - - - - - -
EPS -0.0900 - - - - -
Dividend per Share - - - - - -
Announcement Date 11/18/21 2/28/22 5/12/22 8/10/22 11/14/22 3/30/23
1CAD in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 2.47 4.11 5.6 16.9 22.2 11.5
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow - -6.43 -2.17 -3.56 -3 -0.3
ROE (net income / shareholders' equity) -109% -234% -190% -112% -137% -391%
ROA (Net income/ Total Assets) -53.4% -125% -104% -65.2% -68.9% -59.9%
Assets 1 2.545 7.811 10.73 19.53 30.08 37.38
Book Value Per Share 2 0.1500 0.2000 0.1700 0.3600 0.2300 -0.0300
Cash Flow per Share 2 0.1400 0.1400 0.1600 0.3700 0.3800 0.2000
Capex - - 0 0 0.02 0.01
Capex / Sales - - - - - -
Announcement Date 3/20/19 4/29/20 4/8/21 2/28/22 3/30/23 4/17/24
1CAD in Million2CAD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
2.11 CAD
Average target price
5 CAD
Spread / Average Target
+136.97%
Consensus

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
NERVGEN PHARMA CORP. Stock NervGen Pharma Corp.
-21.85% 108M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
LONZA GROUP AG Stock Lonza Group AG
+47.64% 41.61B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. NGEN Stock
  4. Financials NervGen Pharma Corp.